Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
GE Healthcare
>
another nail in the coffin
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="Anonymous, post: 3195901"]Fact of the matter is Omniscan has the most free roaming Gd of any of the agents on the market and one of the worst in terms of thermodynamic stability of all agents approved. It has more excess chelate than any of the approved agents in the US and is the least stable molecule only to Opimark, which no one uses. It doesn't take a scientist to know those facts. They are all in the package inserts. If it was no different than all of the others why does it have 90% of the confirmed cases of NSF when Magnevist has by far the largest marketshare in the world and very little confirmed cases. Double the marketshare three times less cases doesn't add up. Prohance and Multihance don't have confirmed cases but the marketshare is null.[/QUOTE]</p><p><br /></p>
[QUOTE="Anonymous, post: 3195901"]Fact of the matter is Omniscan has the most free roaming Gd of any of the agents on the market and one of the worst in terms of thermodynamic stability of all agents approved. It has more excess chelate than any of the approved agents in the US and is the least stable molecule only to Opimark, which no one uses. It doesn't take a scientist to know those facts. They are all in the package inserts. If it was no different than all of the others why does it have 90% of the confirmed cases of NSF when Magnevist has by far the largest marketshare in the world and very little confirmed cases. Double the marketshare three times less cases doesn't add up. Prohance and Multihance don't have confirmed cases but the marketshare is null.[/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
GE Healthcare
>
another nail in the coffin
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
GE Healthcare
>
another nail in the coffin
>